URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Medicare drug spending is climbing faster than expected, driven by surging use of GLP-1 medicines and ongoing fallout from Democrats’ Part D redesign.
Also, Enliven’s leukemia drug has encouraging early data, Novartis is expanding its molecular glue ambitions, and SonoThera raised $125 million to advance an ultrasound-based approach to gene delivery.
Please follow us:
